A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders	CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, neuromyelitis optica, optic nerve disorder, optic neuritis, paraneoplastic syndrome, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy	Recruiting	Phase 1	2026-09-09		NCT06680037

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
TG Therapeutics, Inc.	16

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
TG Therapeutics Investigational Trial Site	Omaha	United States	1
TG Therapeutics Investigational Trial Site	La Jolla	United States	1
TG Therapeutics Investigational Trial Site	Cleveland	United States	3
TG Therapeutics Investigational Trial Site	Ann Arbor	United States	2
TG Therapeutics Investigational Trial Site	Milwaukee	United States	3
TG Therapeutics Investigational Trial Site	New York	United States	2
TG Therapeutics Investigational Trial Site	Rochester	United States	1
TG Therapeutics Investigational Trial Site	Columbus	United States	1